AMH decline during chemotherapy reflects breast cancer cell DNA damage response (DDR) proficiency: the ONCO AMH1 pilot study
Germline BRCA1/2 status influences AMH decline during neo-adjuvant CT with drugs inducing DNA lesions. AMH decay is positively related to tumor size change assessed by imaging in gBRCApv patients. However, no conclusions can be drawn regarding the relationship with treatment response assessed by histological criteria.
Authors
- Audrey Mailliez (ORCID: https://orcid.org/0000-0002-0475-8631)
- Emmanuelle D’Orazio
- Anne-Laure Gagez (ORCID: https://orcid.org/0000-0002-7797-3455)
- Christine Decanter (ORCID: https://orcid.org/0000-0002-8232-3959)
- A. Dassonneville
- Pascal Pigny (ORCID: https://orcid.org/0000-0003-3926-4487)
- Hélène Béhal
Institutions
- Inserm (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Hôpital Albert Calmette (FR)
- Centre for Medically Assisted Procreation (CH)
- Centre Oscar Lambret (FR)
- Onco Lille (FR)
Publication Details
- Journal
- Journal of Assisted Reproduction and Genetics
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1007/s10815-025-03475-9
- Primary Topic
- DNA Repair Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centre hospitalier régional universitaire de Lille